TICKERNERD
Menu
KVUEKVUEConsumer Defensive · Household & Personal Products

KVUE Stock Forecast: Kenvue, Inc. Price Predictions for 2026-2027

Last close, 11 Sept 2026
$18
−0.06% on the day

The 14 Wall Street analysts covering Kenvue, Inc. hold a median 12-month price target of $19 — +6.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 64 of 100 as at 12 Sept 2026 — in the upper half.

Market cap
$34.2B
Ticker Nerd rank
64 / 100
Median analyst target
$19
Analysts covering
14
Revenue$4.0B+3.0% y/y
Operating income$758.0M
Net income$456.0M
Free cash flow$624.0M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−6.2%
1M
−5.6%
YTD
+6.6%
1Y
−1.2%
From 52W high
−9.3%
From 52W low
+32.0%
$13
$20
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

KVUE stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Kenvue, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 12 Sept 2026
64 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Volatility
94
Value
79
Issuance
79
Quality
63
Growth
57
Accruals
53
Momentum
52
Revisions
51
Size
7

Volatility (94): The share price has been relatively steady.

Revisions (51): Analysts have, on balance, been cutting their forecasts.

Size (7): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

KVUE stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on KVUE, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$12$14$16$18$20$22$24Oct 25Jan 26Apr 26Jul 26KVUEHigh $23Median $19Low $18

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says14 analysts
2 Buy12 Hold0 Sell
Low $18Median $19High $23

The green dot is the last close — the median target sits +6.9% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 2 moved their price target up and 3 moved it down.

DateFirmActionRatingTarget
11 Aug 2026UBSMaintainsNeutral$20 → $19
21 July 2026BarclaysMaintainsEqual-Weight$18 → $19
21 July 2026BarclaysMaintainsEqual-Weight—
16 July 2026UBSMaintainsNeutral$18 → $20
16 July 2026UBSMaintainsNeutral—
15 Apr 2026CitigroupMaintainsNeutral$20 → $19
15 Apr 2026CitigroupMaintainsNeutral—
14 Apr 2026BarclaysMaintainsEqual-Weight$19 → $18
14 Apr 2026BarclaysMaintainsEqual-Weight—
7 Apr 2026UBSMaintainsNeutral—
6 Mar 2026BarclaysMaintainsEqual-Weight—
18 Feb 2026Canaccord GenuityMaintainsHold—
18 Feb 2026CitigroupMaintainsNeutral—
18 Feb 2026UBSMaintainsNeutral—
30 Jan 2026JefferiesDowngradeHold—
10 Nov 2025BarclaysMaintainsEqual-Weight—
29 Oct 2025Canaccord GenuityDowngradeHold—
27 Oct 2025JefferiesMaintainsBuy—
10 Oct 2025JP MorganMaintainsOverweight—
9 Oct 2025CitigroupMaintainsNeutral—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. KVUE appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

KVUE vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 11 Sept 2026, Kenvue, Inc. returned −1.2% against +17.5% for the S&P 500, dividends included.

KVUE vs S&P 500, last 12 monthsTotal return, rebased to 100
708090100110120Oct 25Jan 26Apr 26Jul 26KVUES&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

KVUE analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
−0.5%
Analysts raising
2
Analysts cutting
9
Fundamentals

Kenvue, Inc. (KVUE) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
20.9×

Cheaper than 36% of US stocks

Price / sales
2.2×

Cheaper than 50% of US stocks

Price / book
3.2×

Cheaper than 30% of US stocks

EV / EBITDA
12.0×

Cheaper than 31% of US stocks

Growth & margins
Revenue growth (YoY)
3.0%

Higher than 34% of US stocks

Earnings growth (YoY)
8.6%

Higher than 46% of US stocks

Gross margin
58.2%

Higher than 71% of US stocks

Operating margin
19.4%

Higher than 79% of US stocks

Net margin
10.8%

Higher than 71% of US stocks

Returns & dividend
Return on equity
15.6%

Higher than 75% of US stocks

Return on assets
7.0%

Higher than 85% of US stocks

Dividend yield
4.7%

Higher than 81% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Kenvue, Inc. (KVUE) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Kenvue, Inc. has a market value of $34.2B and an enterprise value of $41.7B.

  • Revenue in the twelve months to 30 June 2026: $15.4B. The latest quarter grew 3.0% year on year.

  • Net income over the same four quarters: $1.7B, a 10.8% net margin.

  • Diluted earnings per share, trailing twelve months: $0.87.

  • Free cash flow in the twelve months to 30 June 2026: $1.9B.

  • Kenvue, Inc. spent $70.0M on share buybacks and $1.6B on dividends in the twelve months to 30 June 2026.

  • Shares outstanding: 1.9B.

  • Trailing P/E: 20.9×; forward P/E: 14.3× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 4.73%, paying out 98% of earnings.

  • Kenvue, Inc. employs 21,780 people — $707K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 12 Sept 2026

Data provided by Twelve Data

Peers

KVUE vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelHousehold & Personal Products
CompanyMarket capTKN rank
KVUEKenvue, Inc.$34.2B
64
ELThe Estée Lauder Companies, Inc.$33.9B
83
KMBKimberly-Clark Corp.$32.6B
63
CHDChurch & Dwight Co., Inc.$22.3B
68
CLColgate-Palmolive Co.$70.0B
94
CLXThe Clorox Co.$10.7B
29
ELFe.l.f. Beauty, Inc.$5.8B
38

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Kenvue, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest KVUE news & analysis

Kimberly-Clark's 54-Year Dividend Streak Faces Its Biggest Test Yet With $48.7 Billion Kenvue Deal

24/7 Wall Street · 12 Sept 2026neutral

Kimberly-Clark raised its dividend for the 54th consecutive year while pursuing a roughly $48.7 billion acquisition involving Kenvue, prompting income investors to assess whether a deal of that size can coexist with a dividend payout that costs over $1.

Why it matters — KVUE watchers would care because the scale of the Kenvue deal raises questions about how the acquisition and Kimberly-Clark's long-standing dividend commitment will coexist.

My Favorite Consumer Staples Play Right Now

ETF Trends · 12 Sept 2026neutral

The article discusses why owning consumer staples stocks is essential for dividend investing strategies, highlighting them as a source of income and a vehicle for compounding wealth through dividend reinvestment. It presents consumer staples as a favored sector for income-focused investors.

Why it matters — As a consumer staples company, Kenvue watchers would care because the article underscores the appeal of this sector for dividend-focused investors.

Kenvue Declares Quarterly Cash Dividend

Business Wire · 10 Sept 2026neutral

Kenvue Inc. announced that its Board of Directors declared a quarterly dividend of $0.21 per share on its common stock. The dividend is payable on October 2, 2026, to shareholders of record as of the close of business on September 21, 2026.

Why it matters — This announcement confirms Kenvue's ongoing shareholder return program, providing investors with clarity on the company's upcoming dividend payment schedule.

Kenvue's Brand Strength and Innovation Strategy Support Growth

Zacks Investment Research · 8 Sept 2026positive

Zacks highlights that Kenvue's trusted brands, innovation efforts, and productivity initiatives support its growth as the company strengthens its consumer health portfolio and global reach.

Why it matters — A KVUE watcher would care because it underscores the company's strategic pillars for continued growth in its consumer health portfolio and international expansion.

American Century Value Fund Q2 2026 Contributors And Detractors

Seeking Alpha · 8 Sept 2026neutral

American Century Value Fund reported double-digit gains for U.S. equities in Q2 2026 despite volatility from the Iran conflict. Key contributors included Infineon Technologies, Teradyne, and Walmart, while Micron Technology, Intel, and Sandisk were key detractors.

Why it matters — The report does not mention Kenvue, so it offers limited insight for KVUE watchers beyond broader equity-market context.

FAQ

Frequently asked questions about KVUE stock

What is the KVUE stock price forecast for 2026-2027?

The 14 Wall Street analysts covering Kenvue, Inc. have a median 12-month price target of $19, with estimates ranging from $18 to $23. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is KVUE stock a buy right now?

Of the 14 analysts covering Kenvue, Inc., 2 rate it a Buy, 12 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Kenvue, Inc. 64 out of 100 across roughly 4,600 US stocks as at 12 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank KVUE?

As at 12 Sept 2026, Kenvue, Inc. ranks 64 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (94 of 100).

Will KVUE stock go up?

No one can know that. What the data says: the median 12-month target from 14 analysts implies +6.9% from the last close, and Ticker Nerd's factor model ranks Kenvue, Inc. 64 out of 100 as at 12 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the KVUE stock forecast for 2030?

No analyst covering Kenvue, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for KVUE are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $18 to $23 over the next 12 months.

How has KVUE stock performed over the past year?

Kenvue, Inc. returned -1.2% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Kenvue, Inc. do?

Kenvue Inc. is a consumer health company focused on everyday care products across self care, skin health and beauty, and essential health.

What is the latest news on KVUE?

The most recent item we track (24/7 Wall Street, 12 Sept 2026): "Kimberly-Clark's 54-Year Dividend Streak Faces Its Biggest Test Yet With $48.7 Billion Kenvue Deal". Kimberly-Clark raised its dividend for the 54th consecutive year while pursuing a roughly $48.7 billion acquisition involving Kenvue, prompting income investors to assess whether a deal of that size can coexist with a dividend payout that costs over $1.

Company

About Kenvue, Inc.

Kenvue Inc. is a consumer health company focused on everyday care products across self care, skin health and beauty, and essential health. Kenvue’s portfolio includes well-known brands such as Tylenol, Neutrogena, Aveeno, Listerine, Johnson’s, BAND-AID Brand, Zyrtec, and Nicorette, serving needs in pain relief, cough and allergy care, skincare, oral care, baby care, wound care, and smoking cessation. The company sells products to consumers and healthcare professionals across North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. As a pure-play consumer health business, Kenvue plays a significant role in the global over-the-counter and personal care markets, combining science-backed formulations with mass-market brand recognition.

CEO Mr. Kirk L. Perry · 21,780 employees · United States · https://www.kenvue.com